[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-complications":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,51,79,105,160,181,219,245,275,297,330,372,403,427,451,477,501,522,545,603,625],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100534267","hybrid-closed-loop-effectiveness-trial-in-adults-with-type-1-diabetes-100534267",false,"NCT06236607","Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes","Inclusion Criteria:\n\n* Clinical diagnosis of T1D for at least 12 months, on MDI for at least 6 months;\n* A1c ≥7.0% with no upper limit at screening (The investigator will consider the participant A1c level, compliance with current diabetes management, and prior acute diabetic complications. For this reason, there is no upper limit on A1c specified for eligibility);\n* Able to understand, speak and read English (Given the language limitations in currently available pump interfaces, subjects who are not able to understand written English will not be eligible);\n* Willingness to use either lispro or aspart insulin and no other insulin or new non-insulin diabetes pharmacotherapy during the study;\n* Total daily dose of insulin of at least 10 units\u002Fday;\n* Investigator believes that the participant will be able to successfully adhere to the study protocol.\n\nExclusion Criteria:\n\n* Current use of insulin pump or closed loop insulin pump system;\n* Unable to provide informed consent;\n* Currently taking hydroxyurea or have medical condition that may necessitate use of hydroxyurea;\n* Current use of SGLT-2 inhibitors or sulfonylureas (If using GLP-1RA, pramlintide or metformin, must be on a stable dose for 3 months prior to enrollment);\n* Tape allergy or skin condition precluding use of pump or CGM;\n* Females who are pregnant or intending to become pregnant (since automated algorithm adaption for some of the HCL systems used in the trial cannot be configured to adjust to changing insulin demands of pregnancy);\n* Current renal dialysis or plan to begin renal dialysis during study. Most recent eGFR \\\u003C30 ml\u002Fmin is exclusionary (within last 2 years is acceptable);\n* Active cancer treatment;\n* Extreme visual or hearing impairment that would impair ability to use CGM and pump;\n* Cognitive concerns;\n* Significant psychiatric diagnosis or substance abuse disorder that in the investigator's opinion impairs ability of the individual to participate.","ALL","18 Years","75 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23],"NA","Minoritized individuals with type 1 diabetes (T1D) have approximately 2% higher average A1c levels and twice the rate of hospitalizations, complications, and mortality as their white counterparts. However, the efficacy trials establishing the benefits of hybrid closed loop (HCL) pump therapy in T1D have been in more socially advantaged and predominantly non-Hispanic white patients. Use of this technology by individuals with T1D from underserved communities remains very low.\n\nThe investigators plan to conduct a randomized effectiveness trial - with broader eligibility criteria (including markedly elevated A1c) and longer follow up than the previous HCL efficacy trials - to evaluate the benefits, safety risks and treatment complications of HCL use in underserved adults with T1D. A comprehensive mixed-methods approach will be implemented to capture information about the user experience.\n\nParticipants will be randomized (3:1 ratio) to one of three FDA-approved HCL systems or continuous glucose monitoring and multiple daily injection therapy. Subjects will be followed for 9 months to collect data on effectiveness (glucose % time-in-range 70-180 mg\u002FdL and % time \\\u003C 70 mg\u002FdL), safety (diabetic ketoacidosis and severe hypoglycemia events) and patient experience using the systems (including benefits and burdens, the impact of life stressors on HCL use, and how the match between HCL system functionality and the individual's needs and expectations impacts on user experience).",[26,27],"Diabetes Mellitus, Type 1","Diabetes Complications",[29,30,31,32,33,34,35,36,37],"Hybrid closed loop (HCL)","HCL pump therapy","Multiple daily injections (MDI)","Continuous glucose monitoring (CGM)","Glucose time-in-range (TIR)","Glucose management indicator (GMI)","Diabetic ketoacidosis","Patient reported outcomes (PRO)","Ecological momentary assessment (EMA)","RECRUITING","2026-03-30",{"date":41,"type":42},"2026-04-01","ACTUAL",{"date":44,"type":42},"2025-02-27",{"date":46,"type":20},"2028-09",{"name":48,"class":49},"Boston Medical Center","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100623081","new-diagnostic-tool-minion-for-identifying-microorganisms-in-foot-wounds-of-patients-living-with-diabetic-foot-osteomyelitis-100623081","NCT07391995","New Diagnostic Tool (MinION) for Identifying Microorganisms in Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis","Evaluation of a New Diagnostic Tool (MinION) for Identifying Microorganisms in the Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis (DFOM)","MINI-OS","Inclusion Criteria:\n\n* N\u002FA\n\nExclusion Criteria:\n\n* N\u002FA",{"count":60,"type":20},43,"OBSERVATIONAL","Diabetic foot wound infections are predominantly polymicrobial. However, 'conventional' microbiological culture does not identify all the bacteria potentially involved in these infections and requires time, which can have a negative impact by delaying treatment and\u002For the prescription of appropriate antibiotic therapy.\n\nReal-time metagenomics analysis using Oxford Nanopore Technologies' MinION technology has demonstrated sufficient power to identify virtually all microbial genomes in a given sample, providing additional information on their antibiotic resistance profile and in silico prediction of genes encoding virulence factors within than 4 hours. Based on these rapid results, a management protocol could be defined specifically for each patient with a view to personalised medicine.\n\nThe aim is to study the diversity of bacterial and fungal species identified using the MinION method and compare this diversity with the results obtained using conventional methods (routine culture) from bone biopsies taken from DFOM patients.",[64,27,65],"Diabetes Mellitus","Diabetic Peripheral Neuropathy",[67,68],"Foot Ulcer, Diabetic","Infection","2026-02-10",{"date":71,"type":42},"2026-02-11",{"date":73,"type":42},"2026-01-01",{"date":75,"type":20},"2026-12",{"name":77,"class":49},"Centre Hospitalier Universitaire de Nīmes",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":15,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":78},"100316754","human-ipsc-for-repair-of-vasodegenerative-vessels-in-diabetic-retinopathy-100316754","NCT03403699","Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy","iPSC","Inclusion Criteria:\n\n* Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must either carry the diagnosis of diabetes or be a healthy aged control and b) the patient be willing and have the ability to cooperate with the eye exam and skin punch biopsy protocol.\n\nExclusion Criteria:\n\n* We will apply the following exclusion criteria: a) evidence of ongoing acute or chronic infection (HIV, Hepatitis B or C, tuberculosis); b) ongoing malignancy; c) cerebral vascular accident or cerebral vascular procedure; d) current pregnancy; e) history of organ transplantation; f) presence of a graft (to avoid any effect of the graft on inflammatory parameters; and g) patients with anemia. Subjects with AMD, glaucoma, uveitis, known hereditary degenerations or other significant ocular complications other than diabetic retinopathy will be excluded.",true,"21 Years","98 Years",{"count":90,"type":20},20,"This study proposes to carefully examine the hypothesis that human inducible pluripotent stem cells (iPSCs) can be effectively employed as a future therapeutic option for individuals with diabetic retinopathy and macular ischemia. iPSCs will be generated from the peripheral blood cells of subjects with diabetes and age matched controls. The human iPSC cells will be used to generate mesoderm cells for injection into the vitreous cavity of diabetic rodents and primate eyes. The ability of mesoderm cells to generate endothelial cells and pericytes in areas of degenerated capillaries will be examined. The human iPSCs will also be used to generate hematopoietic CD34+CD45+ cells. The combination of CD34+CD45+ cells derived from iPSCs and iPSC derived mesoderm will be examined in combination for their potentially beneficial effect to enhance the vessel formation.",[27,93],"Diabetic Retinopathy",[95],"inducible pluripotent stem cells","2026-01-20",{"date":98,"type":42},"2026-01-22",{"date":100,"type":42},"2018-01-11",{"date":102,"type":20},"2027-12-31",{"name":104,"class":49},"University of Alabama at Birmingham",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":115,"conditions":116,"keywords":136,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":159},"100609246","precision-subclassification-of-mental-health-in-diabetes-digital-twins-for-precision-mental-health-to-track-subgroups-100609246","NCT07212075","Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups","TwinPeaks","Inclusion Criteria:\n\n* 18 to 80 years of age\n* Diagnosis of type 1 diabetes or type 2 diabetes or other specific type of diabetes\n* Diabetes duration ≥ 1 year\n* Sufficient German language skills\n* Informed consent\n\nExclusion Criteria:\n\n* Inability to consent\n* Significant cognitive impairment (e.g. dementia)\n* Severe disorder or condition impacting the person's ability to participate in the study or likely to confound results (e.g. treated cancer, heart disease ≥ NYHA III, schizophrenia\u002Fpsychotic disorder)\n* Terminal illness\n* Being bedridden","80 Years",{"count":114,"type":20},1809,"Mental conditions and disorders (e.g. distress, depressive, anxiety, and eating disorders) are more prevalent in people with diabetes (PWD) and associated with reduced quality of life and impaired glycaemic outcomes. Evidence supports a complex network between psychosocial factors and glycaemic control that can be highly variable between persons. It is assumed that subgroups exist that show different trajectories of glycaemia and mental health.\n\nBelonging to a particular subgroup may be linked with a higher risk of developing mental health problems compared to others. This suggests that it is possible to treat individuals in different subgroups in a manner that optimizes their treatment and can improve health outcomes. Accurate characterisation can inform more individualized care. This calls for a more personalised approach considering the idiosyncrasies of different subgroups.\n\nOver 3 years, the investigators have established the basis of a precision mental health approach for diabetes using n-of-1 analyses. By utilizing combined ecological momentary assessment (EMA: repeated daily sampling of psychosocial factors in everyday life) and continuous glucose monitoring (CGM), intensive longitudinal data per person could be collected. This enables the analysis of individual associations between glycaemic parameters and psychosocial variables and identification of individual sources of diabetes distress in each person.\n\nThe objective of the present study is to use of the n-of-1 approach to identify subgroups of PWD who share common characteristics in the associations between glucose and psychosocial variables. The identified subgroups shall be used to develop a digital twin for precision mental health in diabetes. The digital twin serves as representation of a real person, allowing to make simulations and predictions of the course of mental health and glycaemia. These predictions can inform diabetes care and lead to more precise, personalised treatment decisions.\n\nTo achieve this, a longitudinal panel including over 1,400 PWD who continuously complete EMA and questionnaire surveys and measure glucose levels using CGM was developed. Over 1000 clinical interviews to diagnose mental disorders have been conducted to identify major mental health conditions and map mental outcomes. To identify subgroups and develop the digital twin, the sampling will be expanded aiming at a total of 1,809 PWD. Incidence and remission of mental disorders will be determined via repeated interviews.\n\nThe complex networks between clinical, metabolic, and psychosocial data will be analysed using machine learning, leading to new insights with the potential to shape future guidelines. These results will be used by the digital twin to predict courses of glycaemic control and mental health, translating the individual evidence into direct treatment suggestions.",[117,118,119,120,121,27,122,123,124,125,126,127,128,129,130,131,132,133,134,135],"Diabetes (DM)","Diabete Mellitus","Diabete Type 1","Diabete Type 2","Diabetes Distress","Depression - Major Depressive Disorder","Depression Anxiety Disorder","Depression Bipolar","Depression Disorders","Anxiety Disorder (Panic Disorder or GAD)","Anxiety Disorder NOS","Eating Disorder Binge","Anorexia Nervosa","Bulimia Nervosa","Eating Disorder Not Otherwise Specified","Depressed Mood","Anxiety Symptoms","Disordered Eating Behaviors","Fear of Hypoglycemia",[137,138,139,140,141,142,143,144,145,146,64,147,148,149,150,121,110],"Digital Twin","Precision Medicine","Precision Mental Health","Subclassification","Trajectories","Subtypes","Person-reported Outcomes (PRO)","Ecological Momentary Assessment (EMA)","Continuous Glucose Monitoring (CGM)","People with Diabetes (PWD)","HbA1c","Depression","Anxiety","Eating disorder","2025-11-27",{"date":153,"type":42},"2025-12-04",{"date":155,"type":42},"2025-01-01",{"date":102,"type":20},{"name":158,"class":49},"Forschungsinstitut der Diabetes Akademie Mergentheim",3,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":78},"100524368","a-fruit-and-vegetable-prescription-program-100524368","NCT06107816","A Fruit and Vegetable Prescription Program","A Pilot, 3-arm Randomized Controlled Trial of a Fruit and Vegetable Prescription Program for Patients With Type Two Diabetes","Inclusion Criteria:\n\n* Patient at Penn State Health St. Joe's Medical Center\n* Diagnosis of Type 2 Diabetes Mellitus greater than or equal to six months\n* A1c level is greater than or equal to 7% (53 mmol\u002Fmol)\n* Low income defined as enrolled in Supplemental Nutrition Assistance Program (SNAP), is uninsured or have Medicaid, or identifying as food insecure based on USDA criteria.\n* Ability to give a blood sample\n* Willing to respond to contacts from study staff over the study period\n* Willing and able to give informed consent\n* Can read and write in English or Spanish\n\nExclusion Criteria:\n\n* Diagnosis of Type 2 Diabetes Mellitus less than six months\n* Patients who have previously participated in the Veggie Rx program in the past year\n* Patients who have attended any diabetes self-management education and support (DSME\u002FS) sessions in the past year\n* Women who are pregnant or who plan to become pregnant during the study period\n* Any uncontrolled mental illness or substance abuse, or inpatient treatment for these in the past six months\n* Any unstable or significant medical condition in the past 3 months (e.g. recent heart attack, stroke, DVT)\n* A1c level is less than 7%\n* Does not speak English or Spanish\n* Inability to provide informed consent\n* Unable to give a blood sample",{"count":168,"type":20},120,[23],"Dietary intake of fruits and vegetables (F\\&V) is a cornerstone for the treatment of type 2 diabetes, however less than 16% of Hispanic adults consume the recommended number of servings each day. F\\&V prescription (F\\&V Rx) programs are embedded into clinical settings and provide patients with vouchers to purchase F\\&V at local retailers. The proposed study aims to test the effects of a F\\&V Rx on diabetes self-management education and support (DSME\u002FS) uptake and retention, dietary intake of F\\&V and diet quality, glucose control (hemoglobin A1c), and program implementation outcomes.",[64,27],"2025-11-18",{"date":174,"type":42},"2025-11-21",{"date":176,"type":42},"2024-07-26",{"date":178,"type":20},"2027-07",{"name":180,"class":49},"Milton S. Hershey Medical Center",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":199,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":78},"100607937","thai-painpredict-validation-study-100607937","NCT07195045","Thai PainPREDICT Validation Study","Thai Version of PainPREDICT: Translation, Validation, and Mobile Application Development for Screening Painful Diabetic Neuropathy in Diabetes Patients","PainPREDICT-Th","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed with type 1 diabetes mellitus or type 2 diabetes mellitus.\n* Able to communicate in Thai.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of neuropathy due to other causes (e.g., alcohol, chemotherapy, HIV, other systemic diseases).\n* Significant cognitive impairment or neurological conditions that prevent comprehension of the questionnaire.\n* Severe psychiatric illness that interferes with study participation.",{"count":190,"type":20},277,[23],"Painful diabetic neuropathy (PDN) is one of the most common and disabling complications of diabetes mellitus, substantially affecting quality of life, daily functioning, and health system burden. Early identification of PDN is crucial for timely treatment, prevention of complications such as foot ulcers and amputations, and for reducing healthcare costs. However, in Thailand there are limited culturally adapted and validated tools for screening PDN. PainPREDICT is an internationally validated questionnaire designed to characterize neuropathic pain profiles, but its adaptation for Thai patients has not yet been undertaken. In parallel, the use of mobile health technologies (mHealth) has the potential to expand access to screening and monitoring of chronic conditions, particularly in resource-limited settings.",[194,195,196,197,198,27],"Painful Diabetic Neuropathy (PDN)","Diabetic Neuropathy, Distal Symmetric Polyneuropathy (Manifestation)","Type 1 Diabetes Mellitus (T1DM)","Type 2 Diabetes Mellitus (T2DM)","Neuropathic Pain",[200,201,202,203,204,205,206,207,208,209,27,210],"PainPREDICT","Painful Diabetic Neuropathy","Diabetic Neuropathy","Neuropathic Pain Questionnaire","Mobile Health (mHealth)","Questionnaire Validation","Screening Tool","Thai Population","Cross-Cultural Adaptation","Digital Health Application","Neuropathy Screening","2025-09-29",{"date":213,"type":42},"2025-10-03",{"date":215,"type":42},"2025-08-28",{"date":102,"type":20},{"name":218,"class":49},"Chulalongkorn University",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":78},"100607421","characteristics-of-diabetic-foot-ulcer-patients-100607421","NCT07188337","Characteristics of Diabetic Foot Ulcer Patients","Examining the Demographic, Clinical, and Laboratory Data of Patients With Diabetic Foot Ulcers Admitted to 5 Azar Hospital in 2024 (Registry Project)","Inclusion Criteria:\n\n* Patients admitted to 5 Azar Hospital, Gorgan, in 2024\n* Diagnosis of diabetic foot ulcer (DFU) confirmed by medical records\n* Complete demographic, clinical, and laboratory data available in medical files\n\nExclusion Criteria:\n\n* Incomplete or missing medical records\n* Patients with foot ulcers of non-diabetic etiology\n* Patients whose key laboratory data are unavailable",{"count":227,"type":20},200,"This study examines the demographic, clinical, and laboratory characteristics of patients with diabetic foot ulcers admitted to 5 Azar Hospital, Gorgan, in 2024. By analyzing factors such as Hb, WBC, HbA1C, ESR, and CRP in relation to ulcer severity, the study aims to identify predictors of outcomes and support more effective prevention and management strategies",[230,27],"Diabetic Foot Ulcer",[232,233,234,235],"diabetic foot ulcer","diabetes mellitus","amputation","neuropathy","2025-09-20",{"date":238,"type":42},"2025-09-23",{"date":240,"type":42},"2025-07-27",{"date":242,"type":20},"2025-11",{"name":244,"class":49},"Golestan University of Medical sciences",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":15,"minAge":251,"maxAge":16,"enrollmentInfo":252,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":254,"conditions":255,"keywords":260,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":78},"100451542","early-detection-of-long-term-diabetic-complications-in-children-and-adolescents-with-type-1-diabetes-100451542","NCT05159856","Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes","Inclusion Criteria:\n\n* T1D\\>12 months\n* 6-18 years old prior to inclusion\n* Followed at the Pediatric Diabetes outpatient clinic at Steno Diabetes Center Copenhagen\n* Speaks and reads Danish well enough to understanding the given oral and written information.\n* There is a written consent from the guardianship holder\u002Fholders for the child.\n\nExclusion Criteria:\n\n* T1D \\\u003C 12 months\n* Known cardiovascular disease\n* Antihypertensive treatment","6 Years",{"count":253,"type":20},400,"Aims: To investigate early markers of long-term diabetic complications and the association to an extended glucose metabolic profile comprising glucose control (current and past), glucose variability and insulin sensitivity in children and adolescents with type 1 diabetes (T1D).\n\nBackground: Most Danish children and adolescents with T1D do not achieve their metabolic target and are at increased risk of developing long-term diabetic complications, reducing their life expectancy and increase their morbidity rate. Hence, improved metabolic control, a better understanding of what optimal metabolic control means, combined with detailed monitoring of the first markers of long-term complications and their reversibility or lack thereof are needed.\n\nMethods: A prospectivel study of 400 children, aged 6-18 years old, with T1D\\>12 months. Early markers of long-term diabetic complications will be investigated as arterial stiffness, nerve dysfunction and nephropathy. Data on T1D onset, duration, treatment modality, self-monitoring-blood-glucose profiles, growth, weight, and pubertal status will be collected.\n\nBlood sampling will include routine tests and markers of glucose, lipid, bone, and gastrointestinal metabolism. DXA-scan, Fibroscan, bone-age, eye-examination and physical activity will be measured. Data on retrospective glucose- and lipid-profiles will be collected. The children will be offered a followup every 5 years for the next two decades.\n\nPerspectives: This study provides novel insight into the frequency of early markers of long-term diabetic complications and its association to the interplay of the pancreas, adipose, gastrointestinal and bone metabolic axis. Which can assist in identifying subgroups of children and adolescents requiring earlier in-depth screening for early markers of long-term diabetic complications, for putative interventions for prevention, hence reducing morbidity and mortality in T1D.",[27,256,257,258,259],"type1diabetes","Children, Only","Diabetic Neuropathies","Arterial Stiffness",[261,262,263,235,264,265],"pediatric","arteriel stiffness","pulse wave velosity","type 1 diabetes","early diabetic complications","2025-05-28",{"date":268,"type":42},"2025-06-03",{"date":270,"type":42},"2022-05-03",{"date":272,"type":20},"2025-12",{"name":274,"class":49},"Steno Diabetes Center Copenhagen",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":86,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":287,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":50},"100445008","benefits-of-insoles-with-real-time-alert-and-foot-self-care-education-100445008","NCT05074849","Benefits of Insoles With Real-Time Alert and Foot Self-Care Education","Benefits of Insoles With Real-Time Alert and Foot Self-Care Education in Improving Adherence for Prescribed Footwear in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Men or women 18 years old or older,\n* Diagnosis of Diabetes Mellitus,\n* Ambulatory, Uses prescribed diabetes footwear.\n* Those willing and able to attend follow up visits such as long distance (i.e. greater than 30 miles to recruitment sites).\n* Those able to read or follow directions.\n\nExclusion Criteria:\n\n* Active Charcot Arthropathy or major foot deformity,\n* Cardiopulmonary disease (e.g. recent MI, Stroke),\n* Gangrene, active infection. Montreal Cognitive Assessment (MOCA\\\u003C20).\n* Wide spread malignancy or systemically immunocompromising disease.",{"count":283,"type":20},72,[23],"Novel approaches to promote adherence to diabetic footwear and prevent high incidence of diabetes foot ulcers are urgently needed. Investigators propose to translate an innovative and practical technology to supplement clinical and risk evaluation for patients with diabetes through wearable insoles and smart watch, along with foot self-care education, to improve adherence to prescribed footwear and reduce incidence of foot ulcers in those with diabetes and at risk for foot ulcers.",[27],"NOT_YET_RECRUITING","2025-04-11",{"date":290,"type":42},"2025-04-16",{"date":292,"type":20},"2026-10-20",{"date":294,"type":20},"2026-12-30",{"name":296,"class":49},"Texas Woman's University",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":15,"minAge":304,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":310,"conditions":311,"keywords":320,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":328,"locationsCount":78},"100486191","phase-1-efficacy-of-adipose-tissue-derived-stem-cells-for-the-treatment-of-diabetic-foot-ulcers-100486191","NCT05610865","Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers","Autologous Adipose Tissue Derived Stromal Vascular Fraction Versus Cultured Adipose Derived Stem Cells for the Treatment of Chronic Diabetic Wounds","Inclusion Criteria:\n\n* Type 1 or Type 2 Diabetes Mellitus\n* Age 20-60 years (Male\u002FFemale)\n* Body mass index 20-30 kg\u002Fm2\n* Suitable for liposuction\n* Condition or Disease: Diabetic Neuropathy\n* Wound Type: Chronic foot ulcer\n* Approx. wound area: 2 cm2 - 8 cm2\n* Wound Condition should be of Wagner's grade I (Limited to soft tissue)\n* Duration of wound persistence: 6-24 Weeks\n* Transcutaneous oxygen pressure \\> 30 mmHg, and an ankle brachial pressure index \\> 0.5.\n* Already following an adequate off-loading method\n* Provided signed informed consent\n\nExclusion Criteria:\n\n* Uncontrolled hyperglycemia (HbAlc \\> 9%)\n* Presence of severe clinical sign of infection\n* Inability to tolerate off-loading, and poor prognosis diseases including malignant tumors.\n* Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases\n* Patients with critical limb ischemia and osteomylitis\n* Withdrawal of informed consent","20 Years","60 Years",{"count":307,"type":20},28,[309],"PHASE1","The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will increase the pragmatic potential of both types of cells as PRP is rich in survival and chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety of its use in diabetic patients and will unveil the more effective therapeutic option for treatment of foot ulcer wounds.",[230,64,312,313,314,315,316,317,27,318,319],"Diabetic Foot","Diabetic Foot Infection","Diabetic Foot Ulcer Neuropathic","Foot Ulcer Due to Type 1 Diabetes Mellitus","Foot Ulcer Due to Type 2 Diabetes Mellitus","Foot Ulcer","Chronic Diabetic Ulcer of Left Foot","Chronic Diabetic Foot Ulcer of Right Foot",[321],"Stromal vascular fraction (SVF), Adipose derived stem cells (ASCs), Diabetic foot ulcer (DFU), Platelet rich plasma (PRP)","2024-12-30",{"date":324,"type":42},"2024-12-31",{"date":326,"type":42},"2020-11-20",{"date":272,"type":20},{"name":329,"class":49},"University of the Punjab",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":21,"phases":340,"briefSummary":341,"conditions":342,"keywords":357,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":367,"leadSponsor":369,"locationsCount":78},"100567960","clinical-trial-assessing-human-placental-membrane-products-and-standard-of-care-versus-standard-of-care-in-nonhealing-dfus-and-vlus-100567960","NCT06674980","Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs","A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.","C5CAMP","Inclusion Criteria for DFU:\n\n1. At least 18 years of age or older.\n2. Must have diagnosis of type 1 or 2 Diabetes mellitus.\n3. At enrollment, subject must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the imaging device.\n4. Must have a target ulcer that has been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care, prior to screening visit.\n5. Target ulcer located on the foot with at least 50% of the ulcer below the malleolus.\n6. Target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.\n7. Subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and \\\u003C= 1.3\n   2. TBI \\>= 0.6\n   3. TCOM \\>= 40 mmHg\n   4. PVR: biphasic\n8. If subject has two or more ulcers, they must be separated by 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n9. Target ulcer must be located on the plantar aspect of the foot and must be offloaded for at least 14 days prior to enrollment.\n10. Subject must consent to using the prescribed offloading method for the duration of the study.\n11. Subject must agree to attend weekly study visits.\n12. Subject must be willing and able to participate in the consent process.\n\nExclusion Criteria for DFU:\n\n1. Subject is known to have a life expectancy of \\\u003C 6 months.\n2. Subject's target ulcer is not secondary to diabetes.\n3. Target ulcer is infected or there is cellulitis in the surrounding skin.\n4. Target ulcer exposes tendon or bone.\n5. Evidence of osteomyelitis complicating the target ulcer.\n6. Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.\n7. The subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n8. Subject is taking hydroxyurea.\n9. Subject has applied topical steroids to the ulcer surface within one month of initial screening.\n10. Subject has a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.\n11. Subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n12. The surface area of the subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n13. The surface area measurement of the subject's target ulcer decreases by 20% or more during the active 2-week screening phase.\n14. Subject has acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.\n15. Subject is a woman who is pregnant or considering becoming pregnant in the next 6 months.\n16. Subject has end stage renal disease requiring dialysis.\n17. Subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.\n18. The subject, in opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.\n19. Subject was treated with hyperbaric oxygen therapy or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to screening.\n20. Subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n\nInclusion Criteria for VLU:\n\nPotential subjects are required to meet all the following criteria for enrollment in the study.\n\n1. Subjects must be at least 18 years of age or older.\n2. At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20 cm2 measured post-debridement.\n3. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.\n4. No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks.\n5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and ≤ 1.3;\n   2. TBI ≥ 0.6;\n   3. TCOM ≥ 40 mmHg;\n   4. PVR: biphasic.\n6. If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n7. The potential subject must agree to attend the weekly study visits required by the protocol.\n8. The potential subject must be willing and able to participate in the informed consent process.\n\nExclusion Criteria for VLU:\n\n1. The potential subject is known to have a life expectancy of \\\u003C 6 months.\n2. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.\n3. The target ulcer exposes tendon or bone.\n4. There is evidence of osteomyelitis complicating the target ulcer.\n5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n8. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n9. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.\n10. Women who are pregnant or considering becoming pregnant within the next 6 months.\n11. The potential subject has end stage renal disease requiring dialysis.\n12. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.\n13. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n14. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n15. The subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n16. A subject has a wound with active or latent infection is excluded.\n17. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.",{"count":339,"type":20},177,[23],"The purpose of the study is to evaluate the efficacy of multiple human placental membrane products and Standard of Care (SOC) versus SOC alone in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) over 12 weeks using a modified platform trial design.",[343,64,344,345,346,347,348,349,350,351,352,27,258,353,312,317,354,355,356],"Pathologic Processes","Glucose Metabolism Disorders","Metabolic Diseases","Endocrine System Disease","Diabetic Angiopathies","Vascular Diseases","Cardiovascular Diseases","Leg Ulcer","Skin Ulcer","Skin Diseases","Foot Diseases","Diabetes Mellitus, Type 2","Ulcer","Foot Ulcer Unhealed",[358,359,360,361,362],"Human Placental Membrane (HPM)","Diabetic Foot Ulcer (DFU)","Venous Leg Ulcer (VLU)","Cellular, Acellular, and Matrix-like Product (CAMP)","Cellular and\u002For Tissue-Based Product (CTP)","2024-12-20",{"date":365,"type":42},"2024-12-27",{"date":363,"type":42},{"date":368,"type":20},"2027-01-22",{"name":370,"class":371},"C5 Biomedical","INDUSTRY",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":380,"targetDuration":4,"studyType":21,"phases":382,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":287,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":400,"locationsCount":78},"100501519","phase-2-the-effect-of-roxadustat-on-renal-oxygenation-in-diabetes-nephropathy-100501519","NCT05810311","The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","The Effect of Roxadustat on the Levels of Renal Oxygenation in Patients With Diabetes Nephropathy (FOXTROT)","FOXTROT","Inclusion Criteria:\n\n1. Diabetes mellitus with anemia caused by DKD, and indication for treatment with erythropoetin\u002Ferythropoietin-stimulating drugs.\n2. Age 18-75\n3. HbA1c \\>55\n4. Diabetes duration 10+ years.\n5. Chronic kidney disease (CKD) stage 3-4\n6. Symptomatic anemia with Hb \\\u003C10g\u002Fdl\n7. Contraception: Female subjects must be postmenopausal, surgically sterile, or if premenopausal (and not surgically sterile), be prepared to use ≥1 effective method of contraception during the study and for 30 days after the last visit. Effective methods of contraception are those listed below:\n\n   1. Double barrier method, i.e. (a) condom (male or female) or (b) diaphragm, with spermicide; or\n   2. Intrauterine device; or\n   3. Vasectomy (partner); or\n   4. Hormonal (e.g., contraceptive pill, patch, intramuscular implant, or injection); or\n   5. Abstinence, if in line with the preferred and usual lifestyle of the subject.\n8. Signed informed consent.\n\nExclusion Criteria:\n\n1. Anemia not related to CKD.\n2. Dialysis dependent CKD\n3. Currently treated for renal anemia using erythropoietin-stimulating drugs\n4. Infections during the last 30 days.\n5. Severe hypertension (≥180mmHg systolic or \\>110mmHg diastolic blood pressure)\n6. Liver failure (Child-Pugh class B-C)\n7. History of epilepsy or seizures\n8. Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol.\n9. Ongoing drug or alcohol abuse.\n10. Known allergy to RD or DA\n11. Malignancy\n12. Severe claustrophobia\n13. Participation in another ongoing pharmacological study\n14. If female: plans to become pregnant, known pregnancy or a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or currently breastfeeding.\n15. Unwillingness to participate following oral and written information\n16. Other severe acute or chronic medical or psychiatric condition that makes the subject inappropriate for the study, as judged by the investigator.\n17. History of thrombosis (DVT, pulmonary embolism)",{"count":381,"type":20},30,[383],"PHASE2","The study will investigate if treatment with Roxadustat improves kidney oxygenation in diabetic patients with nephropathy receiving treatment for renal anemia, compared to patients receiving treatment with darbepoetin alpha.\n\nParticipants will be randomized to either treatment, and receive equal care for renal anemia. Kidney oxygenation will be examined before treatment start and after 24 weeks using BOLD-MRI (blood oxygen level-defendant MRI), a non-invasive method available for measurement of tissue oxygenation levels that is comparable with direct invasive measurement of partial oxygen pressure. Blood and urin samples will be collected in connection to these visits. The primary endpoint is the change in medullary and cortical R2\\* (inversely proportional to the tissue oxygenation content) after 24 weeks. Secondary endpoints will be albuminuria and urinary levels of ROS (evaluated by electron paramagnetic resonance (EPR) spectroscopy with CPH spin probes).",[27,386],"Diabetes; Nephropathy (Manifestation)",[388,389,390,391,392,393],"HIF","Hypoxia","Diabetes mellitus","Nephropathy","BOLD-MRI","Kidney oxygenation","2024-11-15",{"date":396,"type":42},"2024-11-19",{"date":398,"type":20},"2025-06-01",{"date":102,"type":20},{"name":401,"class":402},"Region Stockholm","OTHER_GOV",{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":15,"minAge":411,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":21,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":78},"100556123","elderly-patients-with-type-2-diabetes-and-cognitive-exercises-100556123","NCT06520995","Elderly Patients With Type 2 Diabetes and Cognitive Exercises","The Effect of Education Program Supported by Cognitive Exercises in Elderly Individuals With Type 2 Diabetes","DIACOG","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes for at least one year\n* Literate\n* Able to use smartphone\u002Ftablet\u002Fcomputer and have internet access\n* Individuals who agree to participate in the study will be included.\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* With severe cognitive impairment\n* Known neurological or psychiatric disorders\n* Severely depressed\n* Individuals with disabilities (vision, hearing problems, etc.) will not be included in the study","65 Years",{"count":413,"type":20},90,[23],"The study was planned as a single-center, prospective randomized controlled study. Individuals over 65 years of age with type 2 diabetes without severe cognitive impairment will be included in the study. The primary aim of the study is to improve the cognitive functions of the patients after the interventions. The secondary aim is to strengthen patients' diabetes self-management and increase their quality of life, especially by improving their glycemic control. For these purposes, in our study, patients will be randomized into three groups: \"cognitive exercise and diabetes education\", \"diabetes education only\" and \"control\" group. The control group will be provided with standard outpatient diabetes education. Individuals who will be in the \"cognitive exercise and video training\" group will watch a total of 12 diabetes education videos prepared by the researcher, in which a different topic will be discussed every week for 3 months, and they will also participate cognitive exercises for 15-20 minutes a day for 3 months via a mobile application. Individuals in the \"diabetes education only\" group will similarly watch a total of 12 diabetes education videos prepared by the researchers. Patients will be evaluated in terms of cognitive function, psychosocial problems (anxiety, depression, stress), glycemic control (HbA1c), diabetes management and quality of life before the interventions, at 3 months and 6 months.",[417,354,27],"Cognitive Impairment","2024-07-20",{"date":420,"type":42},"2024-07-25",{"date":422,"type":42},"2024-04-01",{"date":424,"type":20},"2025-03-30",{"name":426,"class":49},"Istanbul University - Cerrahpasa",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":78},"100472393","glucose-monitoring-after-acute-myocardial-infarct-in-people-with-diabetes-100472393","NCT05431296","Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes","GLAM","Inclusion Criteria:\n\nFrom the Hammersmith Hospital In-patient Cardiology Services:\n\n* Adults aged \\>18 years\n* Known or newly diagnosed type 2 diabetes\n* Taking one or more oral hypoglycaemic agent, GLP1 receptor analogue and\u002For insulin\n* Admitted to Hammersmith Hospital cardiology inpatient services with ACS\n* Raised blood troponin level on admission\n\nFrom Imperial College Healthcare Trust Diabetes and Cardiology Clinics:\n\n* Adults aged \\>18 years\n* Known type 2 diabetes\n* Previous acute coronary syndrome within the last 10 years but \\> 6 months ago\n* Taking one or more oral hypoglycaemic agent and \u002For GLP1 receptor analogue, and\u002For insulin\n\nExclusion Criteria:\n\nFrom the Hammersmith Hospital In-patient Cardiology Services:\n\n* HbA1c \\\u003C48mmol\u002Fmol\n* People who have previously had bariatric surgery\n* People taking hydroxyurea\n* People who undergo haemodialysis or peritoneal dialysis\n* Unable to participate due to other factors, as assessed by the Chief Investigators\n* Pregnancy as determined by clinical team\n* Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year\n\nFrom Imperial College Healthcare Trust Diabetes and Cardiology Clinics:\n\n* HbA1c \\\u003C48mmol\u002Fmol\n* People who have previously had bariatric surgery\n* People taking hydroxyurea\n* People who undergo haemodialysis or peritoneal dialysis\n* Unable to participate due to other factors, as assessed by the Chief Investigators\n* Pregnancy as determined by clinical team\n* Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year\n* Previous acute coronary syndrome more than 10 years ago or within the last 6 months\n\nWithdrawal criteria\n\n* The subject has a serious event related to the study\n* Investigated initiated discontinuation of study due to participation or equipment concerns\n* Withdrawal of consent",{"count":435,"type":20},160,[23],"Glucose monitoring after Acute Myocardial infarct in people with diabetes is a Dexcom funded study that is investigating whether the use of continuous glucose monitors (Dexcom ONE model) in people with type 2 diabetes facilitates time in glycaemic range in the 6 months after an acute myocardial infarction. As an exploratory outcome it will investigate whether time in glycaemic range is associated with changes in mortality and major adverse cardiac events in the 6 months after acute myocardial infarct.",[439,440,441,27],"Type 2 Diabetes","Acute Myocardial Infarction","Acute Myocardial Infarction With ST Elevation","2024-07-02",{"date":444,"type":42},"2024-07-03",{"date":446,"type":42},"2023-02-07",{"date":448,"type":20},"2025-02",{"name":450,"class":49},"Imperial College London",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":78},"100492487","optimized-care-of-people-with-diabetes-and-foot-complication-in-primary-care-100492487","NCT05692778","Optimized Care of People With Diabetes and Foot Complication in Primary Care","Inclusion Criteria patients:\n\n* Persons with diabetes being treated in Region Västra Götaland\n* Understand spoken and written Swedish\n\nExclusion Criteria:\n\n• Not understand spoken and written Swedish\n\nInclusion Criteria healthcare professionals:\n\n* Professionals working with patients with diabetes having foot complications.\n* Working in Region Västra Götaland\n* Understand spoken and written Swedish",{"count":19,"type":20},"The goal of this observational study is to create and evaluate and new management, by using eHealth tools, to prevent diabetic foot ulcers. The main questions it aims to answer are:\n\n1. Validation\n\n   a. Is a method for foot assessment, that uses eHealth tools, valid regarding its usefulness? b. Is a method for foot assessment, that uses eHealth tools, reliable regarding the generated risk stratification?\n2. Mapping\n\n   1. How do health care professionals and patients with diabetes experience that the future foot examination should be designed?\n   2. What experiences have health care professionals and patients with diabetes to use an eHealth tool supporting the annual foot examination?\n3. Interviews - to use a paper format supporting a structured foot assessment\n\n   a. How do health care professionals experience to use a structured foot form, in paper form?\n4. Interviews - footwear\n\n   a. What factors that influence how patients with diabetes choose their footwear?\n5. Interviews - usability test of using an eHealth tool\n\n   a. How could a digital eHealth tool be designed? b. How could a digital eHealth solution be implemented, managed and spread in public health care setting? i. Participants will:\n\n1\\. fill in questionnaires 2. be interviewed 3. test eHealth solutions supporting the foot examination\n\n6\\. Experiences of using an eHealth tool supporting the foot assessment\n\na. How could a digital eHealth tool be designed?\n\n7\\. Questionnaires regarding self-perceived quality of life, the experiences of the visit at the care unit, transportation to the care unit.\n\na. Patients that visits care fills in a questionnaire regarding self-perceived quality of life (EQ-5D), a modified version of National Patient Survey, the diabetes questionnaire and a questionnaire regarding their travels and time for travels to and from the visit to the care unit.\n\n8\\. Critical evaluation of complexity\n\n1. Exists complexity in the development, test, management, spread and sustain of an eHealth tool supporting foot examination and self-care of the feet in diabetes.\n2. How could a digital eHealth solution be implemented, managed and spread in public health care setting?\n\n   9\\. Long term effect\n\na. What is the long-term effect of using an eHealth tools supporting a structured foot examination?",[460,312,64,354,26,27],"Diabetes",[462,463,464,465,466,467],"diabetes","diabetic foot","eHealth","foot deformities","prevention","co-design","2024-04-16",{"date":470,"type":42},"2024-04-17",{"date":472,"type":42},"2020-01-01",{"date":474,"type":20},"2026-12-31",{"name":476,"class":49},"Sahlgrenska University Hospital",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":21,"phases":488,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":287,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":78},"100512348","quantifying-artificial-pancreas-related-changes-in-diabetic-neuropathy-100512348","NCT05951283","Quantifying Artificial Pancreas-related Changes in Diabetic Neuropathy","A Longitudinal, Single Centre Study to Assess the Effects of Artificial Pancreas-related Changes in Diabetic Neuropathy","QUANT-AP","Inclusion Criteria:\n\nType 1 diabetes aged 18-70 who falls into either of these three categories and has the ability to read and comprehend English:\n\nStarting Artificial Pancreas therapy as determined for clinical need Starting insulin pump therapy as determined for clinical need On multiple daily injection therapy for insulin delivery\n\nExclusion Criteria:\n\n* History of ocular disease that may affect the cornea.\n* History of corneal trauma or surgery (NB cataract surgery does not preclude enrolment unless surgery occurred in the 3 months prior to enrolment date)\n* Concurrent ocular disease, infection or inflammation.\n* History of neuropathy due to alcoholism, renal impairment requiring renal replacement therapy, infectious disease (e.g., Lyme disease, HIV\u002FAIDS, hepatitis B), liver failure, B12 deficiency\n* Unable to read and comprehend English","70 Years",{"count":487,"type":20},102,[23],"A complication of diabetes mellitus is damage to nerves called neuropathy. There are several mechanisms involved that will lead to the development of neuropathy. Neuropathy can lead to foot ulcers, infections and amputations. Patients with neuropathy may also experience pain, which can be difficult to control and the medications are limited by side effects. Despite this there are no approved treatments to reverse the progression of neuropathy and the management of patients is focused on controlling blood glucose and other metabolic factors to prevent neuropathy and its symptoms from getting worse.\n\nPatients with type 1 diabetes are prescribed multiple daily injections (MDI) of insulin to manage their glucose control. However, insulin pump therapy and, more recently, automated insulin delivery (AID) or the Artificial Pancreas can be used as the insulin delivery method for patients with type 1 diabetes mellitus. Manchester Diabetes Centre is the first adult diabetes centre in Europe to pioneer and use a commercially-approved AID in clinical practice.\n\nInsulin pump therapy and AID have the advantage of being able to provide insulin at variable doses, which is closer to the natural process occurring within an individual without diabetes. Both are currently considered to be the most physiological method of insulin delivery and have been shown to improve glycaemic control, quality of life (QOL) and reduce the risk of hypoglycaemia (low blood glucose level). The investigators have previously shown in a small group of people that use of an insulin pump therapy may improve symptoms of painful neuropathy via a more stable glucose profile. The peaks and drops in insulin may make neuropathy worse.\n\nIn this study the investigators aim to investigate the use of insulin pump therapy and AID in their effect on neuropathy. This will be in comparison to a control group of patients on MDI. The investigatorsbwill use a variety of neuropathy measures and symptom questionnaires to assess structural and functional neuropathy status. The investigators hypothesise that those patients receiving the newer technologies will demonstrate an improvement in symptoms and nerve regeneration.\n\nThis finding would have a significant impact for patients as it would provide evidence to suggest that those patients with neuropathy should be put onto an insulin pump or AID to improve neuropathy and its symptoms. As these are treatments that are already available on the NHS to patients satisfying specific criteria this study aims to show benefit in this cohort of patients which can be implemented immediately in clinical practice.",[27,26,258],[460],"2023-10-27",{"date":494,"type":42},"2023-10-30",{"date":496,"type":20},"2023-12-01",{"date":498,"type":20},"2026-07-01",{"name":500,"class":402},"Manchester University NHS Foundation Trust",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":78},"100524676","optimized-diagnosis-and-precision-medicine-of-mody-100524676","NCT06111833","Optimized Diagnosis and Precision Medicine of MODY","Optimized Diagnosis and Precision Medicine of MODY (Maturity-Onset Diabetes of the Young)","Inclusion Criteria:\n\n1. Case Group Diagnosis of diabetes at or before 25 years of age. BMI (Body Mass Index) of 25 kg\u002Fm² or lower. Having at least one parent diagnosed with type 2 diabetes.\n2. Family Group Direct blood relatives of the case group, including brothers and sisters of the case group, who have contacted the research team through the subjects.\n\n   Expressing willingness to participate in this study after granting informed consent.\n3. Control Group Diagnosis of diabetes occurred at or before the age of 40, and the individual lacks typical MODY (Maturity-Onset Diabetes of the Young) characteristics.\n\nAt least one parent has been diagnosed with type 2 diabetes.\n\nExclusion Criteria:\n\n1. Confirmed Diagnosed with type 1 diabetes.\n2. Under 18 years of age.\n3. Unable to personally provide informed consent.\n4. Patients with unrelieved leukemia.\n5. Patients who have undergone chemotherapy or radiation therapy for cancer within the last 12 months.\n6. Cases that have received a blood transfusion within the last six months.\n7. Unwilling or unable to continue treatment follow-up at this hospital.",{"count":509,"type":20},1500,"The goal of this observation is to establish a complete registry for the clinical manifestations, environment, genetic, and other related gene variation information of young-onset diabetic patients. Moreover, according to the physiological and pathological mechanisms of different genes, the impact on the clinical characteristics of diabetes, the therapeutic response to drugs, and the impact on complications will be analyzed.\n\nThe main questions are:\n\n1. The distribution of different types of MODY\n2. The phenotypes and clinical characteristics of different types of MODY\n3. Response to antidiabetic drugs among different types of MODY\n\nOnce the participant is enrolled, their questionnaire information (including disease course and development, health history, family history, drug history, etc.), medication, outpatient\u002Finpatient medical history, etc. will be collected and logged in. Blood and urine samples will also be collected for biochemical tests genetic testing, etc.\n\nAt the same time, the investigators will conduct a continuous follow-up on a regular basis (3 months, 6 months, 12 months, 24 months, and 5 years after the study subject is enrolled).\n\nYoung-onset type 2 diabetes will be compared to see the difference in clinical presentations and responses to antidiabetic drugs.",[512,439,27],"Maturity-Onset Diabetes of the Young (MODY)","2023-10-26",{"date":515,"type":42},"2023-11-01",{"date":517,"type":42},"2023-05-22",{"date":519,"type":20},"2028-05-21",{"name":521,"class":49},"Taichung Veterans General Hospital",{"id":523,"slug":524,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":15,"minAge":87,"maxAge":529,"enrollmentInfo":530,"targetDuration":4,"studyType":21,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":78},"100519461","effectiveness-of-focused-tele-education-in-reducing-diabetes-complications-during-ramadan-100519461","NCT06043843","Effectiveness of Focused Tele-education in Reducing Diabetes Complications During Ramadan","Effectiveness of a Ramadan-focused Structured Diabetes Tele-education in Reducing Diabetes Complications During Ramadan Fasting in South East Asia","Inclusion Criteria:\n\n* Adults with diabetes planning to fast in Ramadan,\n\n  1. Adults with type 2 diabetes aged at least 21 years old,\n  2. Able to fast at least 15 days in Ramadan based on experience of fasting in previous year's Ramadan,\n  3. Underlying type 2 diabetes treated with basal insulin and one or more doses of prandial insulin, or at least twice-daily premixed insulin\n  4. Performed laboratory tests as per standard care - glycated haemoglobin (HbA1c), serum Low Density Lipoprotein- cholesterol, serum triglycerides, serum High Density Lipoprotein- cholesterol, serum Total cholesterol and serum creatinine\n  5. Ability to give informed consent,\n  6. Ability to perform self-monitoring blood glucose\n  7. Have had diabetes-related clinic visits or hospitalization in the past 10 months.\n  8. Have the capacity for video conferencing (internet connection with mobile phone or computer)\n\nExclusion Criteria:\n\n1. Severe diabetes complications including end-stage renal failure\n2. Severe hypoglycemia and hyperglycemic crises within the last 3 months\n3. Advanced comorbidities negating the ability to fast\n4. Pregnancy\n5. Patients on oral medications alone or oral medications plus basal insulin alone\n6. Patients on sulfonylureas","100 Years",{"count":531,"type":20},300,[23],"Introduction Diabetes is a global emergency with detrimental clinical and financial consequences. Poorly managed diabetes leads to a myriad of serious complications, especially cardiovascular and infectious complications, with consequent increased cost and mortality rate. For Muslims in particular, the annual fasting month of Ramadan is one such period when diabetes control is essential. Adequate adjustments in diabetes management need to be made in line with the allowed mealtimes to avoid the risk of diabetes complications during Ramadan.\n\nObjective Investigators aim to investigate the effectiveness of Ramadan-focused structured diabetes tele-education to reduce diabetes complications during Ramadan fasting for Muslims with diabetes in South East Asia.\n\nMethodology In a parallel group randomized controlled trial, investigators aim to recruit 300 adults with diabetes who are able to fast at least 15 days in Ramadan. You will be randomized to the intervention group comprising of a Ramadan-focused structured diabetes tele-education and control group receiving standard care. You will be reviewed again after Ramadan. The primary outcome is the incidence of hypoglycemia in Ramadan. The secondary outcomes are incidence of other diabetes complications in Ramadan episodes including hyperglycemia, episodes of acute infections, attendances in clinic and emergency department, hospital admissions, and compliance to recommendations for diabetes management during Ramadan.\n\nClinical Significance The study enables investigators to evaluate Ramadan-focused structured diabetes tele-education to reduce the risk of diabetes complications for a large population during the fasting month.",[64,535,27],"Fasting","2023-09-12",{"date":538,"type":42},"2023-09-21",{"date":540,"type":42},"2021-02-16",{"date":542,"type":20},"2026-06",{"name":544,"class":49},"Sengkang General Hospital",{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":86,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":21,"phases":554,"briefSummary":555,"conditions":556,"keywords":567,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":78},"100415052","phase-1-mesenchymal-stem-cells-for-the-treatment-of-various-chronic-and-acute-conditions-100415052","NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions","Inclusion Criteria:\n\n* Age 18 and older\n* Ability to provide informed consent\n* Availability for follow up visits\n\nExclusion Criteria:\n\n* Active or recent malignancy (within last 2 years)\n* Pregnancy or breast-feeding\n* Inability to provide informed consent",{"count":553,"type":20},5000,[309,383],"This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.",[557,558,27,559,560,561,562,563,564,565,566],"Autoimmune Diseases","Cardiovascular Disorders","Integumentary Disease","Musculoskeletal Disorders","Neurodegenerative Disorders","Neurologic Disorders","Pulmonary Disorders","Sexual Dysfunction","Urologic Disorders","Viral Illness",[568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,349,591,592,593],"stem cell therapy","umbilical cord stem cells","amniotic stem cells","stem cells","MSC","Mesenchymal Stem Cell","Medicinal Signaling Cell","Erectile Dysfunction","Heart Diseases","Mental Disorders","Neurocognitive Disorders","Neurodegenerative Diseases","Central Nervous System Diseases","Tauopathies","Brain Diseases","Dementia","Disease","Cardiomyopathies","Urologic Diseases","Peripheral Nervous System Diseases","Nervous System Diseases","Alzheimer Disease","Musculoskeletal Diseases","Immune System Diseases","Neuromuscular Diseases","Covid-19","2022-04-27",{"date":596,"type":42},"2022-04-29",{"date":598,"type":42},"2020-07-09",{"date":600,"type":20},"2030-12-09",{"name":602,"class":371},"Thomas Advanced Medical LLC",{"id":604,"slug":605,"hasResults":11,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":610,"targetDuration":612,"studyType":61,"phases":4,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":287,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":78},"100437976","diabetes-complications-and-the-risk-of-cardiovascular-and-cerebrovascular-diseases-100437976","NCT04983277","Diabetes Complications and the Risk of Cardiovascular and Cerebrovascular Diseases","Study of Diabetes Mellitus and Its Complications and the Risk of Cardiovascular and Cerebrovascular Diseases","Inclusion Criteria:\n\n* Diabetic symptoms with: plasma glucose level at any time ≥11.1mmol\u002F L (200mg\u002F dL), or Fasting plasma glucose level ≥7.0mmol\u002F L (126mg\u002F dL), or plasma glucose level ≥11.1mmol\u002F L (200ng\u002F dL) for 2 h in OGTT test, or HbA1c ≥6.5%; Or those without typical symptoms should repeated the tests in another day.\n* Han Chinese.\n* Willingness to participate.\n\nExclusion Criteria:\n\n* Secondary diabetes.\n* Participants in other clinical trials.",{"count":611,"type":20},3000,"1 Week","This study is intended to include 3000 diabetic patients in our hospital to collect complete medical history data, comprehensively improve the screening of diabetic complications and cardiovascular and cerebrovascular risk assessment.",[27,349,615],"Cerebrovascular Disease","2021-07-27",{"date":618,"type":42},"2021-07-30",{"date":620,"type":20},"2021-07",{"date":622,"type":20},"2030-12",{"name":624,"class":49},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":626,"slug":627,"hasResults":11,"nctId":628,"briefTitle":629,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":86,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":632,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":642,"locationsCount":78},"100287519","heidelberg-study-on-diabetes-and-complications-100287519","NCT03022721","Heidelberg Study on Diabetes and Complications","HEIST-DiC","Inclusion Criteria Age between 18 and 75 years Persons with manifest diabetes mellitus type 1 or type 2 and diagnosis according to DDG guidelines 2011, that is HbA1c of 6,5 percent or higher after exclusion of false values, more than 200 mg per dl two hours after glucose in the oGTT, fasting glucose more than 126 mg per dl, spontaneous glucose more than 200 mg per dl at least twice Healthy persons without diabetes or impairment of glucose metabolism in the oGTT according to DDG guidelines 2011 fasting plasma glucose less than 100 mg per dl and 2 hour plasma glucose less than 140 mg per dl Pre diabetics with impaired fasting glucose between 100 mg per dl and 125 mg per dl, or impaired glucose tolerance with 2 hour glucose values between 140 and 199 mg per dl in the oGTT, all values from venous plasma\n\nExclusion Criteria General exclusion criteria Secondary types of Diabetes, ADA criteria type 3 B H Current pregnancy Acute infections or fever Immune suppressant therapy Severe psychiatric diseases requiring treatment, including personality disorders, schizophrenia, depression Known alcohol or drug dependency Severe heart NYHA stadium IV, kidney, or liver insufficiency Non diabetic liver disease, for example PBC, PSC, Wilsons disease, hemochromatosis, autoimmune hepatitis severe peripheral artery disease stadium IV non diabetic glomerulopathy Cancer or other malignant diseases within the last 5 years Infectious diseases like hepatitis B, C, E, or HIV Other severe autoimmune diseases Current participation in an interventional study Anemia or disorders of bone marrow Exclusion criteria for MRI Pacemaker or ICD Metallic and magnetic implants, for example mechanic cardiac valves replacements, joint prostheses, clips after vascular surgery, middle or inner ear implants, recent tooth implants, penile implants Waist circumference more than 135 cm Claustrophobia Allergies against MRI contrast Impaired kidney function with a GFR less than 65 ml per min\n\nExclusion criteria for clamp study Past history of deep vein thrombosis or pulmonary embolism Routine laboratory test results less than 80 percent below lower reference value of Ferritin, iron, leucocytes, hemoglobin, hematocrite, RBC, platelets, blood alcohol Level\n\nExclusion criteria for bioimpedance measurement Pacemaker or ICD\n\nExclusion criteria for lung function testing Ignoring or non understanding of the instructions Body weight more than 160 kg",{"count":633,"type":20},500,"The prospective observational study entitled \"Heidelberg Study on Diabetes and Complications\" is designed to Monitor the presence and development of diabetic complications in type 1 and type 2 diabetic patients, as well as pre-diabetics. Mail Goal is to detect new metabolic mechanisms or new risk factors for the development of diabetic complications in order to identify risk-subgroups. Non-diabetic controls will be enrolled for reference and comparison.",[27],"2017-01-12",{"date":638,"type":20},"2017-01-16",{"date":640,"type":4},"2016-09",{"date":46,"type":20},{"name":643,"class":49},"Heidelberg University"]